




DISCLOSURES


Disclosures/Conflicts of Interest


Scientific Ad Boards and Consulting: Abbott Anthos Bristol Myers Squibb Janssen Perosphere Technologies Pfizer Roche Sanofi


Î




3













ANTITHROMBIN	PROTEIN C	PROTEIN S
Pregnancy		Pregnancy
Liver Disease	Liver Disease	Liver Disease
DIC	DIC	DIC
Nephrotic Syndrome		
Major Surgery		Inflammation
Acute Thrombosis	Acute Thrombosis	Acute Thrombosis
Treatment with:	Treatment with:	Treatment with:
Heparin	Warfarin	Warfarin
Estrogen		Estrogen


<section-header><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item>























Approach to DOAC Selection

Consider:

- Indication for treatment
- Duration of treatment
- Age
- Weight
- Drug-drug interactions
- N/V/D
- Renal function
- Hepatic function
- History and location of bleeding/bleeding risk
 - GI
 - Intracranial
- Niche populations: cancer, APS, ESRD
- Insurance coverage—and timeliness of obtaining drug
- Compliance


Property	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
rioperty	Dabigatian	Kivaroxabali	Аріхаран	Edoxaban
Bioavailability	6 – 7%	80%	66%	45%
Ттах	1.5 hours	2 – 4 hours	1 – 3 hours	1 – 2 hours
Т½	12 – 14 hours	9 – 13 hours	8 – 15 hours	9 – 11 hours
Hepatic Metabolism	No	Yes	Yes	Yes
Drug Interactions	P-gp	CYP3A4/P-gp	СҮРЗА4/	P-gp
			P-gp	
Protein Binding	35%	90%	87%	55%
Renal Elimination	80%	35%	25%	50%
Reversal agent	idarucizumab	Andexanet	Andexanet	Andexanet*
		4F-PCC	4F-PCC	4F-PCC


DOAC Dosing: Factor II Inhibitor


Agent	Route	Prophylaxis	Therapeutic
Dabigatran	РО	SPAF	VTE: Treat with parental agent days 5-10, then
		CrCl > 30: 150mg BID	CrCl > 30: 150mg BID
		CrCl 15-30: 75mg BID	CrCl <30/dialysis: AVOID
		CrCl<15/dialysis: AVOID	


DOAC Dosing: Factor Xa Inhibitors			
Agent	Route	Prophylaxis	Therapeutic
Rivaroxaban	PO	Knee: 10mg daily X 10d	15mg BID x 21 days, then 20mg daily
		Hip: 10mg daily X 35d	Extended (> 6 months): 10mg daily
		SPAF: 20mg daily	
Apixaban	PO	Knee: 2.5mg BID X 12d	10mg BID x 7 days, then 5mg BID
		Hip: 2.5mg BID X 35d	Extended (>6 months): 2.5mg BID
		SPAF: 5mg BID	
Edoxaban	PO	SPAF: 60mg daily	Treat with parental agent days 5-10, then
			>60kg: 60mg daily
			≤60kg: 30mg daily

Apixaban vs rivaroxaban • Top prescribed DOACs • The once-a-day dosing strategy for rivaroxaban compared to twicea-day dosing for apixaban can result in increased bleeding in certain situations: Decreased renal function • Age • GI bleeding n 20 mg once daily (n = 24 • Menorrhagia n 5 mg twice daily ma ng (n = 24 20(g 175 • Understanding the differences can help 150 125 100 75 prescribe the appropriate drug, insurance not withstanding 50 25 0 2









Extremes of Weight: summary of data

 Most trials enrolled patients between 60-100 kg

only 12% in VTE studies had BMI > 35

Current package inserts:

Edoxaban: for VTE treatment reduce dose to 30 mg qd for patients \leq 60 kg

Apixaban: reduce dose for weight \leq 60 kg and if age \geq 80 years or creatinine \geq 1.5 mg/dl

 Use caution in patients <60 kg or >120 kg

	Phase 3 Studies Comparing DOACs with VKA in VTE		VKA in VTE (Including Retrospective and Prospective Studies and Meta-analyses)		
	BMI >35 or BW >120 kg	BMI >40	BMI >35 or BW >120 kg	BMI >40	
Apixaban	х	х	Similar outcomes ⁶	Similar outcomes ^{5,6}	
Dabigatran	х	Х	Х	х	
Edoxaban	х	×	х	х	
Rivaroxaban	Similar outcomes ⁷	Х	Similar outcomes ^{5,8-10}	Similar outcomes ^{5,9}	
Pooled DOAC	Similar outcomes ¹¹	x	Similar outcomes 12-16	Similar outcomes ¹²	

Note: Similar outcome = DOAC compared with LMWH/VKA; X = no available data. Abbreviations: BMI, body mass index, expressed in kg/m²; BW, body weight; DOAC, direct oral anticoagulant; LMWH, low molecular weight heparin; VKA, vitamin K antagonist; VTE, venous thromboembolism.

Martin, JTH, 2021


Phase 4 Studies Comparing DOAC with

Updated Summary Guidance Statements for use of DOACs for VTE in patients with obesity

1) Consistent with the 2016 ISTH SSC recommendations, we conclude that the use of any DOAC is appropriate for patients with BMI up to 40 kg/m² or weight 120 kg. For patients with BMI > 40 kg/m² or weight >120 kg, we recommend that the individual DOACs should be used as follows:

- 2) For treatment of VTE, we suggest that standard doses of rivaroxaban or apixaban are among appropriate anticoagulant options regardless of high BMI and weight. Less supportive data exist for apixaban diam rivaroxaban. Yoo, weight-based LMWH (per manufacturers' recommendations), and fondaparinux are also options.
- 3) For primary prevention of VTE, we suggest that standard doses of rivaroxaban or apixaban are among appropriate anticoagulant options regardless of high BMI and weight. Drug approval is restricted to elective hip and knee arthroplasty and (in some countries) extended VTE prevention following acute medical illness.
- 4) We sugges not to use dabigatran, edoxaban or betrixaban for VTE treatment ind prevention in patients with BMI >40 kg/m² or weight >120 kg, given unconvincing data for dabigatran, and fact or clinical or דאר אין מאנג וויר פלטxaban and betrixaban.
- 5) We suggest not to regularly follow peak or trough drug-specific DOAC levels because there are insufficient data to influence management decisions.
- 6) We sugges not to use DOAC for treatment or prevention of VTE in the acute setting after bariatric surgery because of concerns of decreased absorption), and instead, to initiate such patients on parenteral anticoaguiation in the early postsurgical phase. We suggest that switching to VKA or DOAC may be considered after at least 4 weeks of parenteral treatment, and if so, suggest obtaining a DOAC trough level to check for drug absorption and bioavailability.

Martin et al J Thromb Haemst 2021



Apixaban pharmacokinetics at steady state in hemodialysis patients

5mg bid	Apixaban 5 mg twice daily	Day 22	P Value
	AUC ₀₋₁₂ , ng h/ml	3026.6 ± 46.6% [2770.4]	.03
	AUC ₀₋₂₄ , ng h/ml	6053.2 ± 46.6% (3505.5 - 9469.7)	.03
45-658) –	C _{max} , ng/ml	307.0 ± 39.4% (189.0 - 455.0)	.02
	C _{min} , ng/ml	217.5 ± 51.9% (91.0 - 337.4)	.03
Cmin 111.3 (22-515) t _{max} , h t _{1/2} , h	t _{max} , h	3.8 ± 35.6% (2.5 - 6.0)	.89
	t _{1/2} , h	17.4 ± 51.3% (7.1 - 29.8)	.13
	5 patients, day 15-22: 5 mg	bid apixaban	

Mavrakanas J Am Soc Nephrol. 2017


My Approach for VTE Source patient limited duration Rivaroxaban Apixaban Why: no need for parenteral agent Edoxaban and dabigatran need 5 days of enoxaparin or similar Old patient limited duration Apixaban Why: no need for parenteral agent Apixaban Subsect renal clearance Ises GI bleeding Iower peak intensity anticoagulation Health claims database analysis show lowest bleeding

My Approach for VTE

Special situations

- Must must be able to reverse: dabigatran or warfarin
 - Rivaroxaban and apixaban can use and examet but shorter duration of reversal effect
- Crushed for feeding tube: apixaban, rivaroxaban
- GI disorders prone to bleeding: apixaban
- Cancer associated VTE: apixaban→major bleeding rates are lower than other DOAC
- Extended duration—prophylactic dose for secondary VTE prevention *
 - Rivaroxaban
 - Apixaban

* Usually unprovoked VTE




My Approach for NVAF

- Mitral Valve disease and AF: due to rheumatic valve disease
 - do not use DOAC
 - INVICTUS study: NEJM Aug 28, 2022: rivaroxaban associated with increased mortality compared to VKA

Young patient

- Apixaban
- Dabiagtran--superior for decreased ICH but 80% renal clearance
- Rivaroxaban-once a day
- No: edoxaban if CrCl > 95 ml/min
- Older patient
 - Based on renal function and GI bleed risk:
 - High GI bleed risk
 - Apixaban
 - Edoxaban
 - Low GI bleed risk: any DOAC at appropriate dose




DOAC in mechanical cardiac devices: do not use


Mechanical heart valves

 RE-ALIGN: dabigatran associated with increased strokes compared to warfarin

Eikelboom NEJM 2013

 PROACT Xa: DSMB closed trial Sep 23, 2022 as apixaban associated with increased strokes compared to warfarin with the On-X aortic valve





JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY © 2023 THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. PUBLISHED BY ELSEVIER. ALL RIGHTS RESERVED.


Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes

Meta-Analysis of Randomized Trials

Candrika D. Khairani, MD, MMSc,^{a,*} Antoine Bejjani, MD,^{a,*} Gregory Piazza, MD, MS,^{a,b} David Jimenez, MD, PHD,^c Manuel Monreal, MD, PHD,^d Saurav Chatterjee, MD,^e Vittorio Pengo, MD,^f Scott C. Woller, MD,^{g,h} Josefina Cortes-Hernandez, MD, PHD,ⁱ Jean M. Connors, MD,^j Yogendra Kanthi, MD,^{k,l} Harlan M. Krumholz, MD, SM,^{m,n,o} Saskia Middeldorp, MD, PHD,^p Anna Falanga, MD,^{q,r} Mary Cushman, MD, MSc,^{s,t} Samuel Z. Goldhaber, MD,^{a,b} David A. Garcia, MD,^u Behnood Bikdeli, MD, MS^{a,b,m,v}

Khairani CD, et al. Bikdeli B. J Am Coll Cardiol. doi: 10.1016/j.jacc.2022.10.008.

VOL. 81. NO. 1. 2023



DOAC for cancer associated VTE: good for many

- Both risk of bleeding and recurrent VTE higher in patients with cancer regardless of type of anticoagulant
- Patient selection important when treating cancer associated VTE
- DOAC non-inferior to LMWH, some increased major bleeding
- GI bleeding in patients with GI tract tumors increased with rivaroxaban and edoxaban compared to apixaban and LWMH especially if
 - Non-resected luminal primary and active chemotherapy
- Non-GI tract cancers:
 - assess bleeding risk, problems with absorption, decreased renal function
 - DOAC should be ok if none of the above
- GI tract cancers:
 - Assess location of tumor, metastases
 - Recent GI tract surgery?
 - If yes, avoid DOAC or consider apixaban

Age: dose modification

- Apixaban—age >80 considered a reason to dose reduce in the presence of 1 or more other risk factors for stroke prevention for AF, only DOAC with FDA approved dose adjustment for age.
- VTE studies: mean age 57 years
- AF studies: mean age 71.5 years
- Age and renal insufficiency often concomitantly increased. Traditional methods of assessing CrCl may not apply to patients > 75 yrs+, however renal function not the only factor associated with increased bleeding in the elderly.

DOAC in ESRD: controversial

- Apixaban FDA approved for use in ESRD based on 1 dose given to 16 patients
- Apixaban and rivaroxaban have dosing guidelines for decreased creatinine clearance to 15 ml/min
- Data from many retrospective studies suggest improved outcomes with apixaban vs warfarin for efficacy and safety however:
 - · Highly selected patients, many given reduced dose for unclear reasons
 - patient characteristics that influenced physicians initially to choose apixaban or switch to apixaban from warfarin are unknown
 - Even with propensity score matching and weighting there are significant limitations with this kind of data

Siontis Circulation 2018, Hanni Blood Advances 2020

DOAC in **ESRD**

- RENAL-AF an RCT of warfarin vs apixaban stopped early due to low accrual, loss of funding Pokorney Circ 2022
 - mITT: 82 patients apixaban: 24 on 2.5 bid; 72 warfarin, TTR 44%
 Primary outcome CRNMB: 31.5% apixaban vs 25.5% warfarin
- Need better data to ensure safety
- Data do show sustained increase in peak and trough plasma concentrations compared with patients with normal renal function
 - at least 30% higher, not clear if these are clinically relevant
 - Dosing strategy debated and not known: reduce dose vs full dose?
 - Reversal: if on kidney transplant list would use warfarin
- I rarely use apixaban in patients on dialysis, and only for short term treatment

